Format

Send to

Choose Destination
J Am Acad Dermatol. 2018 Sep 19. pii: S0190-9622(18)32594-5. doi: 10.1016/j.jaad.2018.09.016. [Epub ahead of print]

Lack of an FDA indication should not limit access to appropriate treatment.

Author information

1
Division of Dermatology, Department of Medicine, J.H. Stroger Hospital of Cook County, Chicago, Illinois; Department of Dermatology, Rush Medical College, Chicago, Illinois. Electronic address: Jalbrecht@cookcountyhhs.org.
2
Division of Dermatology, Department of Medicine, Dell Medical School at The University of Texas at Austin, NC.
3
Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
4
Department of Dermatology, University of Wisconsin - Madison.
5
Illinois Dermatology Institute, Chicago, IL.
6
Department of Dermatology, Harvard Medical School, Boston, MA.
7
Department of Dermatology, University of California, San Francisco.
8
Department of Dermatology, Harvard Medical School, Boston, MA; Department of Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston MA.
9
CAPT James Lovell FHCC, Great Lakes, IL; Uniformed Services University of the Health Sciences.
10
Department of Pediatrics, Saint Louis University; Cardinal Glennon Children's Hospital, St. Louis, MO.
11
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX.
12
Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA.
PMID:
30244066
DOI:
10.1016/j.jaad.2018.09.016

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center